Fig. 1From: The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseasePatient flow. Patients included in intent-to-treat and as-treated analyses of sustained virologic response at four weeks after the end of treatment (SVR4) and at 12 weeks after the end of treatment (SVR12)Back to article page